Saisei Pharma plans clinical study of oral MAF in COVID-19 patients

OSAKA, Japan, May 6, 2020 /PRNewswire-PRWeb/ — Saisei Pharma today announced plans to initiate an international clinical trial. The decision is based on published preclinical evidence, preliminary reports from independent studies and is supported by data of the safety and efficacy of oral MAF in conditions that require the involvement of macrophages as the front line defense in innate immunity. Prior studies have indicated that oral MAF can activate macrophage activity at least three-fold within a few minutes after application.

The treatment protocol for prevention and treatment of Coronavirus (COVID-19)

1. For prevention
   
   1. Oral GcMAF (MAF Capsules) therapy
      Take 2-4 capsules per day, depending an age and comorbid diseases.
   2. High dose Vitamin C therapy
      30g, 1 times per week

2. For treatment (A+B or A+B+C+D)

1. 1. Oral GcMAF (MAF Capsules/MAF Powder) therapy

      Take 4 capsules per day – 2 capsules before Breakfast and 2 capsules before bedtime by oral administration

      Take 2 MAF Powder sachets per day – 1 MAF Powder sachet after breakfast and 1 MAF Powder sachet after lunch. Administer by emptying contents of sachet onto the tongue (or open up a MAF capsule). Do not eat or drink anything for 30 minutes after administration.

   2. High dose Vitamin C therapy
      30g, 5 times per week for 2 weeks and then 2-3 times a week

If treatments below are available:

1. 3. GcMAF injection therapy (if available)
      lml GcMAF, 5 times per week for 2 weeks and then 2-3 times per week

1. 4. Intravenous Ozone therapy (if available)
      5 times per week for 2 weeks and then 2-3 times per week